265 related articles for article (PubMed ID: 21527522)
1. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
Narla A; Dutt S; McAuley JR; Al-Shahrour F; Hurst S; McConkey M; Neuberg D; Ebert BL
Blood; 2011 Aug; 118(8):2296-304. PubMed ID: 21527522
[TBL] [Abstract][Full Text] [Related]
2. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
3. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
Ebert BL; Galili N; Tamayo P; Bosco J; Mak R; Pretz J; Tanguturi S; Ladd-Acosta C; Stone R; Golub TR; Raza A
PLoS Med; 2008 Feb; 5(2):e35. PubMed ID: 18271621
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
5. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia.
Sjögren SE; Siva K; Soneji S; George AJ; Winkler M; Jaako P; Wlodarski M; Karlsson S; Hannan RD; Flygare J
Br J Haematol; 2015 Nov; 171(4):517-29. PubMed ID: 26305041
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
9. Steroid resistance in Diamond Blackfan anemia associates with p57Kip2 dysregulation in erythroid progenitors.
Ashley RJ; Yan H; Wang N; Hale J; Dulmovits BM; Papoin J; Olive ME; Udeshi ND; Carr SA; Vlachos A; Lipton JM; Da Costa L; Hillyer C; Kinet S; Taylor N; Mohandas N; Narla A; Blanc L
J Clin Invest; 2020 Apr; 130(4):2097-2110. PubMed ID: 31961825
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Komrokji RS; Lancet JE; List AF
Curr Hematol Malig Rep; 2010 Jan; 5(1):9-14. PubMed ID: 20425391
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
13. Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome.
Yang Z; Keel SB; Shimamura A; Liu L; Gerds AT; Li HY; Wood BL; Scott BL; Abkowitz JL
Sci Transl Med; 2016 May; 8(338):338ra67. PubMed ID: 27169803
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Komrokji RS; List AF
Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
[TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL
Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.
Iskander D; Psaila B; Gerrard G; Chaidos A; En Foong H; Harrington Y; Karnik LC; Roberts I; de la Fuente J; Karadimitris A
Blood; 2015 Apr; 125(16):2553-7. PubMed ID: 25755292
[TBL] [Abstract][Full Text] [Related]
17. Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Keel SB; Phelps S; Sabo KM; O'Leary MN; Kirn-Safran CB; Abkowitz JL
Exp Hematol; 2012 Apr; 40(4):290-4. PubMed ID: 22198155
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
19. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray.
Ebert BL; Lee MM; Pretz JL; Subramanian A; Mak R; Golub TR; Sieff CA
Blood; 2005 Jun; 105(12):4620-6. PubMed ID: 15755903
[TBL] [Abstract][Full Text] [Related]
20. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
